JP2004507231A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004507231A5 JP2004507231A5 JP2002510097A JP2002510097A JP2004507231A5 JP 2004507231 A5 JP2004507231 A5 JP 2004507231A5 JP 2002510097 A JP2002510097 A JP 2002510097A JP 2002510097 A JP2002510097 A JP 2002510097A JP 2004507231 A5 JP2004507231 A5 JP 2004507231A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- antigen
- composition according
- encoding
- immunological epitope
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 description 15
- 239000000427 antigen Substances 0.000 description 11
- 102000038129 antigens Human genes 0.000 description 11
- 108091007172 antigens Proteins 0.000 description 11
- 230000001900 immune effect Effects 0.000 description 10
- 230000000139 costimulatory Effects 0.000 description 4
- 102100006400 CSF2 Human genes 0.000 description 3
- 108050006987 Poxvirus Proteins 0.000 description 3
- 230000000240 adjuvant Effects 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 102000004965 antibodies Human genes 0.000 description 3
- 108090001123 antibodies Proteins 0.000 description 3
- 230000004936 stimulating Effects 0.000 description 3
- 108010084313 CD58 Antigens Proteins 0.000 description 2
- 102100008453 FOLH1 Human genes 0.000 description 2
- 101700036477 FOLH1 Proteins 0.000 description 2
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 2
- 102000015271 Intercellular Adhesion Molecule-1 Human genes 0.000 description 2
- 101700008337 PSMA Proteins 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 description 2
- 229960005486 vaccines Drugs 0.000 description 2
- 229920000160 (ribonucleotides)n+m Polymers 0.000 description 1
- LVTKHGUGBGNBPL-UHFFFAOYSA-N 3-Amino-1,4-dimethyl-5H-pyrido[4,3-b]indole Chemical compound N1C2=CC=CC=C2C2=C1C(C)=C(N)N=C2C LVTKHGUGBGNBPL-UHFFFAOYSA-N 0.000 description 1
- LKKMLIBUAXYLOY-UHFFFAOYSA-N 3-Amino-1-methyl-5H-pyrido[4,3-b]indole Chemical compound N1C2=CC=CC=C2C2=C1C=C(N)N=C2C LKKMLIBUAXYLOY-UHFFFAOYSA-N 0.000 description 1
- 108010082808 4-1BB Ligand Proteins 0.000 description 1
- 101710040446 CD40 Proteins 0.000 description 1
- 102100013137 CD40 Human genes 0.000 description 1
- 101700073334 CD59 Proteins 0.000 description 1
- 102100003281 CD59 Human genes 0.000 description 1
- 102100005830 CD70 Human genes 0.000 description 1
- 101700017377 CD70 Proteins 0.000 description 1
- 102100001891 CTAG1A Human genes 0.000 description 1
- 101710004449 CTAG1A Proteins 0.000 description 1
- 102100007097 DCT Human genes 0.000 description 1
- 101710004105 DCT Proteins 0.000 description 1
- 102000003425 EC 1.14.18.1 Human genes 0.000 description 1
- 108060008724 EC 1.14.18.1 Proteins 0.000 description 1
- 108060002563 EPCAM Proteins 0.000 description 1
- 101700025368 ERBB2 Proteins 0.000 description 1
- 102100016662 ERBB2 Human genes 0.000 description 1
- 102000003951 Erythropoietin Human genes 0.000 description 1
- 108090000394 Erythropoietin Proteins 0.000 description 1
- 101700083116 FOXO1 Proteins 0.000 description 1
- 102000003996 Interferon beta Human genes 0.000 description 1
- 108090000467 Interferon beta Proteins 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 102100008857 MLANA Human genes 0.000 description 1
- 101710012533 MLANA Proteins 0.000 description 1
- 102100006037 MUC1 Human genes 0.000 description 1
- 101700052761 MUC1 Proteins 0.000 description 1
- 102100006044 MUC16 Human genes 0.000 description 1
- 102100013951 MUC2 Human genes 0.000 description 1
- 101700036633 MUC2 Proteins 0.000 description 1
- 102100002997 NPEPPS Human genes 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000004235 Neutropenia Diseases 0.000 description 1
- 229920001850 Nucleic acid sequence Polymers 0.000 description 1
- 101700011681 PAX3 Proteins 0.000 description 1
- 206010033661 Pancytopenia Diseases 0.000 description 1
- 101700044827 RNMT Proteins 0.000 description 1
- 102100011846 TNFSF4 Human genes 0.000 description 1
- 101710025695 TNFSF4 Proteins 0.000 description 1
- 102100003084 TNFSF9 Human genes 0.000 description 1
- 102100019730 TP53 Human genes 0.000 description 1
- 102100007096 TYRP1 Human genes 0.000 description 1
- 101710009757 UROD Proteins 0.000 description 1
- 102100019577 VCAM1 Human genes 0.000 description 1
- 108010000134 Vascular Cell Adhesion Molecule-1 Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 230000000843 anti-fungal Effects 0.000 description 1
- 230000003302 anti-idiotype Effects 0.000 description 1
- 230000000259 anti-tumor Effects 0.000 description 1
- 230000000840 anti-viral Effects 0.000 description 1
- 230000003115 biocidal Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 229920003013 deoxyribonucleic acid Polymers 0.000 description 1
- 108060001540 epmA Proteins 0.000 description 1
- 229940105423 erythropoietin Drugs 0.000 description 1
- 229940044627 gamma-interferon Drugs 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 150000007523 nucleic acids Chemical group 0.000 description 1
- 101700021439 pax3-a Proteins 0.000 description 1
- 101700032819 pax3-b Proteins 0.000 description 1
- -1 peptide Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 108010010447 trophoblastin Proteins 0.000 description 1
Description
【特許請求の範囲】
【請求項１】 顆粒球-単球-コロニー刺激因子（ＧＭ−ＣＳＦ）及び少なくとも１の抗原又は免疫学的エピトープ源をコードする組換えポックスウイルスを含む、医薬組成物。
【請求項２】 少なくとも１の抗原又は免疫学的なエピトープ源が、タンパク質、ペプチド、抗体、抗−イディオタイプ抗体、脂質、炭水化物、細胞、細胞抽出物、細胞フラグメント、少なくとも１の抗原又はその免疫学的エピトープをコードするＤＮＡ、少なくとも１の抗原又はその免疫学的エピトープをコードするＲＮＡ、又は少なくとも一つの抗原又はその免疫学的エピトープをコードするベクターである、請求項1記載の医薬組成物。
【請求項３】 少なくとも１の抗原又は免疫学的なエピトープ源が、少なくとも一つの抗原又はその免疫学的エピトープをコードするベクターであり、前記ベクターがＧＭ−ＣＳＦをコードする組換えポックスウイルスである、請求項1記載の医薬組成物。
【請求項４】 配列番号１〜３６及びこれらの組み合わせからなる群から選択される少なくとも一つのアミノ酸配列を含む免疫学的エピトープを含む、請求項1〜３のいずれか１項記載の医薬組成物。
【請求項５】 ＣＥＡ、ＭＡＲＴ−１、ＭＡＧＥ−１、ＭＡＧＥ−３、ＧＰ−１００、ＭＵＣ−１、ＭＵＣ−２、点変異させたｒａｓオンコジーン、正常又は点変異させたｐ５３、過剰発現されたｐ５３、ＣＡ−１２５、ＰＳＡ、ＰＳＭＡ、Ｃ−ｅｒｂ／Ｂ２、ＢＲＣＡ Ｉ、ＢＲＣＡ ＩＩ、ＰＳＭＡ、チロシナーゼ、ＴＲＰ−１、ＴＲＰ−２、ＮＹ−ＥＳＯ−１、ＴＡＧ７２、ＫＳＡ、ＨＥＲ−２／ｎｅｕ、ｂｃｒ−ａｂｌ、ｐａｘ３−ｆｋｈｒ及びｅｗｓ−ｆｌｉ−１からなる群から選択される抗原を含む、請求項1〜３のいずれか１項記載の医薬組成物。
【請求項６】 少なくとも一つの、共刺激分子、サイトカイン、Ｆｃ受容体−指向的二重特異性抗体、αインターフェロン、βインターフェロン、γインターフェロン、アジュバント、ケモカイン、Ｆｌｔ−３Ｌ、抗生物質、抗真菌剤、抗-ウィルス剤又はエリスロポエチンを含む、請求項１〜５のいずれか１項記載の医薬組成物。
【請求項７】 Ｂ７−１、Ｂ７−２、ＩＣＡＭ−１、ＬＦＡ−３、４−１ＢＢＬ、ＣＤ５９、ＣＤ４０、ＣＤ７０、ＯＸ−４０Ｌ、ＶＣＡＭ−１、これらの哺乳動物ホモログ及びこれらの組み合わせからなる群から選択される共刺激分子を含む、請求項６に記載の医薬組成物。
【請求項８】 組換えポックスウイルスがアビポックスであり、少なくとも１の抗原又は免疫学的エピトープ源がＣＥＡ又はそのエピトープをコードするベクターであり、及び共刺激分子がＢ７又はＢ７．１／ＬＦＡ−３／ＩＣＡＭ−１である、請求項7に記載の医薬組成物。
【請求項９】 請求項１〜８のいずれか1項記載の医薬組成物で感染され、トランスフェクトされ、又は誘導された、単離された細胞。
【請求項１０】 少なくとも１の、共刺激分子又は標的抗原若しくはその免疫学的なエピトープをコードする外来性核酸配列をさらに含む、請求項９に記載の細胞。
【請求項１１】 請求項９又は１０記載の細胞を含む、医薬組成物。
【請求項１２】 免疫応答を向上させるための、請求項１〜８及び１１のいずれか１項記載の医薬組成物。
【請求項１３】 抗-腫瘍応答を向上させるための、請求項１〜８のいずれか1項記載の医薬組成物。
【請求項１４】 好中球減少症を治療するための、請求項１〜８のいずれか1項記載の医薬組成物。
【請求項１５】 血球減少症を治療するための、請求項１〜８のいずれか1項記載の医薬組成物。
【請求項１６】 アジュバント及びワクチンを含む医薬組成物であって、アジュバントが、顆粒球-単球-コロニー刺激因子（ＧＭ−ＣＳＦ）をコードする組換えポックスウイルスであり、ワクチンが腫瘍抗原を含む、前記医薬組成物。
【請求項１７】 American Type Culture CollectionにアクセッションNo. PTA-2099として寄託された、ヒト顆粒球-単球-コロニー刺激因子（ＧＭ−ＣＳＦ）をコードするプラスミドベクター。
[Claims]
1. Granulocyte-monocyte-colony stimulating factor (GM-CSF) andAt least one antigen or immunological epitope sourceCodeRecombinant poxA pharmaceutical composition comprising a virus.
(2) The at least one antigen or source of immunological epitopes encodes a protein, peptide, antibody, anti-idiotype antibody, lipid, carbohydrate, cell, cell extract, cell fragment, at least one antigen or immunological epitope thereof. DNA encoding, RNA encoding at least one antigen or an immunological epitope thereof, or a vector encoding at least one antigen or an immunological epitope thereofThe pharmaceutical composition according to claim 1.
(3) The source of at least one antigen or immunological epitope is a vector encoding at least one antigen or immunological epitope thereof, wherein the vector is a recombinant poxvirus encoding GM-CSFThe pharmaceutical composition according to claim 1.
(4) Comprising an immunological epitope comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 1-36 and combinations thereof, Claim 1~ 3The pharmaceutical composition according to any one of the above.
(5) CEA, MART-1, MAGE-1, MAGE-3, GP-100, MUC-1, MUC-2, point mutated ras oncogene, normal or point mutated p53, overexpressed p53, CA-125 , PSA, PSMA, C-erb / B2, BRCA I, BRCA II, PSMA, tyrosinase, TRP-1, TRP-2, NY-ESO-1, TAG72, KSA, HER-2 / neu, bcr-abl, pax3 -Containing an antigen selected from the group consisting of fkhr and ews-fli-1, Claim 1~ 3The pharmaceutical composition according to any one of the above.
6. At least one costimulatory molecule, cytokine, Fc receptor-directed bispecific antibody, alpha interferon, beta interferon, gamma interferon, adjuvant, chemokine, Flt-3L, antibiotic, antifungal, anti-viral Or contains erythropoietin, Claims1 to6. The pharmaceutical composition according to any one of items 5 to 5.
7. Selected from the group consisting of B7-1, B7-2, ICAM-1, LFA-3, 4-1BBL, CD59, CD40, CD70, OX-40L, VCAM-1, these mammalian homologs and combinations thereof. Contains costimulatory moleculesThe pharmaceutical composition according to claim 6.
8. The recombinant poxvirus is avipox, the source of at least one antigen or immunological epitope is CEA or a vector encoding that epitope, and the costimulatory molecule is B7 or B7.1 / LFA-3 / ICAM-1. is there,A pharmaceutical composition according to claim 7.
9. An isolated cell infected, transfected or induced with the pharmaceutical composition of any one of claims 1 to 8.
10. 10. The cell of claim 9, further comprising at least one exogenous nucleic acid sequence encoding a costimulatory molecule or a target antigen or immunological epitope thereof.
11. Including the cell according to claim 9 or 10,Pharmaceutical composition.
12. To improve the immune response,ClaimAny one of 1 to 8 and 11The pharmaceutical composition according to any one of the preceding claims.
Claim 13 For improving anti-tumor response, Claim 18The pharmaceutical composition according to any one of the above.
14. For treating neutropenia, Claim 18The pharmaceutical composition according to any one of the above.
15. For treating cytopenia, Claim 18The pharmaceutical composition according to any one of the above.
16. A pharmaceutical composition comprising an adjuvant and a vaccine, wherein the adjuvant is a recombinant poxvirus encoding granulocyte-monocyte-colony stimulating factor (GM-CSF) and the vaccine comprises a tumor antigen..
17. Plasmid vector encoding human granulocyte-monocyte-colony stimulating factor (GM-CSF), deposited at the American Type Culture Collection as Accession No. PTA-2099.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US21171700P | 2000-06-15 | 2000-06-15 | |
| PCT/US2001/019201 WO2001095919A2 (en) | 2000-06-15 | 2001-06-15 | A recombinant non-replicating virus expressing gm-csf and uses thereof to enhance immune responses |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004507231A JP2004507231A (en) | 2004-03-11 |
| JP2004507231A5 true JP2004507231A5 (en) | 2008-07-31 |
Family
ID=22788060
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002510097A Pending JP2004507231A (en) | 2000-06-15 | 2001-06-15 | Recombinant non-replicating virus expressing GM-CSF and use thereof for enhancing an immune response |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP1292694A2 (en) |
| JP (1) | JP2004507231A (en) |
| AU (2) | AU6845201A (en) |
| CA (1) | CA2412050C (en) |
| WO (1) | WO2001095919A2 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7271433B2 (en) | 2017-03-13 | 2023-05-11 | フダン ユニバーシティ | Immunostimulants, immunotherapeutic pharmaceutical compositions, and their preparation and use |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AUPQ755300A0 (en) | 2000-05-17 | 2000-06-08 | Monash University | Immune potentiating compositions |
| US7628980B2 (en) | 2000-11-23 | 2009-12-08 | Bavarian Nordic A/S | Modified vaccinia virus ankara for the vaccination of neonates |
| US6684646B2 (en) | 2001-05-22 | 2004-02-03 | Integrated Biosystems, Inc. | Systems and methods for freezing, storing and thawing biopharmaceutical material |
| DK1420822T4 (en) | 2002-04-19 | 2017-10-09 | Bavarian Nordic As | Modified vaccinia virus Ankara for vaccination of newborns |
| AU2003900767A0 (en) * | 2003-02-21 | 2003-03-13 | St Vincent's Hospital Sydney Limited | Idiotypic vaccine |
| BRPI0413334A (en) * | 2003-09-05 | 2006-10-10 | Sanofi Pasteur Ltd | multigene vectors for melanoma |
| WO2005047483A2 (en) | 2003-11-12 | 2005-05-26 | Medical Research Council | Renta: an hiv immunogen and uses thereof |
| EP1769000B1 (en) * | 2004-07-16 | 2014-12-24 | Amgen Research (Munich) GmbH | Expression-enhanced polypeptides |
| CA2654324A1 (en) | 2006-06-02 | 2007-12-13 | International Aids Vaccine Initiative | Hiv-1 clade a consensus sequences, antigens, and transgenes |
| US10603351B2 (en) | 2008-08-21 | 2020-03-31 | Turnstone Limited Partnership | Engineered synergistic oncolytic viral symbiosis |
| CN102281897A (en) * | 2008-10-31 | 2011-12-14 | T·S·顾巴 | Vaccination with poxvirus vectors via mechanical epidermal disruption |
| US8691502B2 (en) | 2008-10-31 | 2014-04-08 | Tremrx, Inc. | T-cell vaccination with viral vectors via mechanical epidermal disruption |
| WO2012149038A1 (en) | 2011-04-25 | 2012-11-01 | Advanced Bioscience Laboratories, Inc. | Truncated hiv envelope proteins (env), methods and compositions related thereto |
| CA2832109C (en) | 2011-06-10 | 2021-07-06 | Oregon Health & Science University | Cmv glycoproteins and recombinant vectors |
| US9402894B2 (en) | 2011-10-27 | 2016-08-02 | International Aids Vaccine Initiative | Viral particles derived from an enveloped virus |
| WO2013093629A2 (en) | 2011-12-20 | 2013-06-27 | Netherlands Cancer Institute | Modular vaccines, methods and compositions related thereto |
| US9347065B2 (en) | 2012-03-29 | 2016-05-24 | International Aids Vaccine Initiative | Methods to improve vector expression and genetic stability |
| EP2679596B1 (en) | 2012-06-27 | 2017-04-12 | International Aids Vaccine Initiative | HIV-1 env glycoprotein variant |
| WO2014040025A2 (en) | 2012-09-10 | 2014-03-13 | International Aids Vaccine Initiative | Immunogens of hiv-1 broadly neutralizing antibodies, methods of generation and uses thereof |
| US20150065381A1 (en) | 2013-09-05 | 2015-03-05 | International Aids Vaccine Initiative | Methods of identifying novel hiv-1 immunogens |
| EP2873423B1 (en) | 2013-10-07 | 2017-05-31 | International Aids Vaccine Initiative | Soluble hiv-1 envelope glycoprotein trimers |
| KR102395820B1 (en) * | 2013-11-05 | 2022-05-09 | 버베리안 노딕 에이/에스 | Combination therapy for treating cancer with a poxvirus expressing a tumor antigen and an antagonist and/or agonist of an immune checkpoint inhibitor |
| WO2015171975A1 (en) | 2014-05-09 | 2015-11-12 | The Regents Of The University Of Michigan | Use of modified banana lectin in purification of glycoproteins |
| US10093720B2 (en) | 2014-06-11 | 2018-10-09 | International Aids Vaccine Initiative | Broadly neutralizing antibody and uses thereof |
| JP5917626B2 (en) * | 2014-07-28 | 2016-05-18 | トレムアールエックス， インコーポレイテッド | Vaccination with poxvirus vectors via mechanical epidermal destruction |
| EP3072901A1 (en) | 2015-03-23 | 2016-09-28 | International Aids Vaccine Initiative | Soluble hiv-1 envelope glycoprotein trimers |
| US9925258B2 (en) | 2015-10-02 | 2018-03-27 | International Aids Vaccine Initiative | Replication-competent VSV-HIV Env vaccines |
| TWI733719B (en) | 2015-12-07 | 2021-07-21 | 美商河谷控股Ｉｐ有限責任公司 | Improved compositions and methods for viral delivery of neoepitopes and uses thereof |
| KR20210070338A (en) * | 2018-10-04 | 2021-06-14 | 에스큐지 바이오테크놀로지스 컴퍼니 | Intracellular delivery of biomolecules to enhance antigen-presenting cell function |
| TW202146427A (en) | 2020-02-21 | 2021-12-16 | 美商國際愛滋病疫苗開發股份有限公司 | Vaccine compositions for preventing coronavirus disease |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5833975A (en) * | 1989-03-08 | 1998-11-10 | Virogenetics Corporation | Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence |
| WO1996011279A2 (en) * | 1994-10-03 | 1996-04-18 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Enhanced immune response by introduction of cytokine gene and/or costimulatory molecule b7 gene in a recombinant virus expressing system |
| AU4448597A (en) * | 1996-10-04 | 1998-05-05 | Connaught Laboratories Limited | Treatment of cancer using a recombinant poxvirus containing nucleic acid sequence encoding a cytokine |
-
2001
- 2001-06-15 JP JP2002510097A patent/JP2004507231A/en active Pending
- 2001-06-15 EP EP01946395A patent/EP1292694A2/en not_active Ceased
- 2001-06-15 AU AU6845201A patent/AU6845201A/en active Pending
- 2001-06-15 CA CA2412050A patent/CA2412050C/en not_active Expired - Lifetime
- 2001-06-15 WO PCT/US2001/019201 patent/WO2001095919A2/en active Application Filing
- 2001-06-15 AU AU2001268452A patent/AU2001268452B2/en not_active Expired
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7271433B2 (en) | 2017-03-13 | 2023-05-11 | フダン ユニバーシティ | Immunostimulants, immunotherapeutic pharmaceutical compositions, and their preparation and use |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004507231A5 (en) | ||
| EP2809788B1 (en) | Adenoviruses expressing heterologous tumor-associated antigens | |
| Surman et al. | Cutting edge: CD4+ T cell control of CD8+ T cell reactivity to a model tumor antigen | |
| CA2354024A1 (en) | A recombinant vector expressing multiple costimulatory molecules and uses thereof | |
| US6855320B2 (en) | Fusion of non-hemolytic, truncated form of listeriolysin O to antigens to enhance immunogenicity | |
| KR102351555B1 (en) | Immunity enhancing therapeutic vaccine for hpv and related diseases | |
| CA2412050A1 (en) | A recombinant non-replicating virus expressing gm-csf and uses thereof to enhance immune responses | |
| CA2293692A1 (en) | Methods and reagents for vaccination which generate a cd8 t cell immune response | |
| JP2003535824A (en) | Epitope tuning in antigen presenting cells | |
| Petrulio et al. | Development of the PANVAC™-VF vaccine for pancreatic cancer | |
| Qazi et al. | Enhancement of DNA vaccine potency by linkage of Plasmodium falciparum malarial antigen gene fused with a fragment of HSP70 gene | |
| JP2024059879A (en) | Teleost fish invariant chain cancer vaccine | |
| Li et al. | A novel therapeutic vaccine composed of a rearranged human papillomavirus type 16 E6/E7 fusion protein and Fms-like tyrosine kinase-3 ligand induces CD8+ T cell responses and antitumor effect | |
| Lin et al. | DNA vaccines encoding IL-2 linked to HPV-16 E7 antigen generate enhanced E7-specific CTL responses and antitumor activity | |
| JP2009279006A (en) | Epitope synchronization in antigen presenting cell | |
| US20050100558A1 (en) | Heterologous boosting immunizations | |
| WO1997039771A1 (en) | Heterologous boosting immunizations | |
| CN115820696A (en) | Therapeutic multivalent HPV mRNA vaccines and methods of making the same | |
| CN110168086B (en) | malaria vaccine | |
| TWI259206B (en) | A DNA vaccine containing a tumor associated gene and a cytokine gene and the method producing thereof | |
| Smahel et al. | DNA vaccine against oncogenic hamster cells transformed by HPV16 E6/E7 oncogenes and the activated ras oncogene. | |
| RU2808567C2 (en) | Invariant chain cancer vaccine from teleost fish | |
| US8921534B2 (en) | Enhancement of the immune response using CD36-binding domain | |
| Wysocki et al. | The 14th European Immunology Meeting-EFIS 2000 | |
| Chamberlain et al. | THE USE OF RECOMBINANT POXVIRUSES AS A PARADIGM FOR THE DEVELOPMENT OF ANTI-CANCER VACCINES |